PT980252E - Terapias para insuficiencia renal aguda - Google Patents
Terapias para insuficiencia renal agudaInfo
- Publication number
- PT980252E PT980252E PT98919715T PT98919715T PT980252E PT 980252 E PT980252 E PT 980252E PT 98919715 T PT98919715 T PT 98919715T PT 98919715 T PT98919715 T PT 98919715T PT 980252 E PT980252 E PT 980252E
- Authority
- PT
- Portugal
- Prior art keywords
- acute renal
- therapies
- renal insufficiency
- risk
- treatment
- Prior art date
Links
- 208000009304 Acute Kidney Injury Diseases 0.000 title abstract 2
- 208000033626 Renal failure acute Diseases 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 208000012998 acute renal failure Diseases 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 1
- 230000005779 cell damage Effects 0.000 abstract 1
- 208000037887 cell injury Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 230000002188 osteogenic effect Effects 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4561997P | 1997-05-05 | 1997-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT980252E true PT980252E (pt) | 2005-01-31 |
Family
ID=21938961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98919715T PT980252E (pt) | 1997-05-05 | 1998-05-05 | Terapias para insuficiencia renal aguda |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100105621A1 (enExample) |
| EP (1) | EP0980252B1 (enExample) |
| JP (2) | JP5033276B2 (enExample) |
| AT (1) | ATE278414T1 (enExample) |
| AU (1) | AU743510B2 (enExample) |
| CA (1) | CA2289123A1 (enExample) |
| DE (1) | DE69826854T2 (enExample) |
| DK (1) | DK0980252T3 (enExample) |
| ES (1) | ES2226125T3 (enExample) |
| PT (1) | PT980252E (enExample) |
| WO (1) | WO1998050060A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612046B2 (en) | 2000-01-31 | 2009-11-03 | Uwe Waldemar Rothenpieler | Method for treating kidney disorders |
| DK1255569T3 (da) * | 2000-01-31 | 2010-12-06 | Uwe Waldemar Rothenpieler | Pax2 til behandling af nyresygdomme |
| US7498352B2 (en) | 2001-06-26 | 2009-03-03 | Takeda Pharmaceutical Company Limited | TGF-β superfamily production/secretion promoter |
| JP2006516020A (ja) * | 2002-08-28 | 2006-06-15 | キュリス インコーポレイテッド | 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与 |
| RU2282899C2 (ru) * | 2004-01-09 | 2006-08-27 | ГОУ ВПО Омская Государственная Медицинская Академия | Способ моделирования инфекции мочевой системы |
| US7598364B2 (en) * | 2005-11-14 | 2009-10-06 | Merial Limited | Plasmid encoding canine BMP-7 |
| JP5175729B2 (ja) | 2006-07-21 | 2013-04-03 | 中外製薬株式会社 | 腎疾患治療剤 |
| US8979797B2 (en) * | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| US10349640B2 (en) | 2014-02-07 | 2019-07-16 | Toru Miyazaki | Preventive or therapeutic agent for kidney disease |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (it) | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4627839A (en) * | 1985-11-21 | 1986-12-09 | American Hospital Supply Corporation | Patient controlled analgesia conversion |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5011691A (en) * | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5045452A (en) * | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| EP0429570B1 (en) | 1989-03-28 | 1998-01-14 | Genetics Institute, Inc. | Osteoinductive compositions |
| ATE209251T1 (de) | 1990-05-16 | 2001-12-15 | Genetics Inst | Knochen- und knorpel-bildung hervorrufende proteine |
| JPH0426624A (ja) | 1990-05-18 | 1992-01-29 | Tsumura & Co | 慢性腎不全改善剤 |
| ATE146076T1 (de) | 1990-06-22 | 1996-12-15 | Du Pont | Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| US7056882B2 (en) * | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| CA2104678C (en) * | 1991-03-11 | 2002-05-14 | Charles M. Cohen | Protein-induced morphogenesis |
| US6194376B1 (en) * | 1991-03-11 | 2001-02-27 | Creative Biomolecules, Inc. | Method for modulating inflammatory response comprising administering morphogen |
| JP3627985B2 (ja) | 1991-03-11 | 2005-03-09 | キュリス インコーポレイテッド | タンパク質により誘導される形態形成 |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| ES2149776T5 (es) * | 1991-08-30 | 2004-07-01 | Curis, Inc. | Modulacion, inducida por un morfogeno, de la respuesta inflamatoria. |
| ATE308336T1 (de) * | 1991-08-30 | 2005-11-15 | Curis Inc | Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten |
| JP3616089B2 (ja) | 1991-08-30 | 2005-02-02 | キュリス インコーポレイテッド | 形態形成誘導蛋白のスクリーニング方法 |
| US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| JP3981405B2 (ja) | 1992-07-31 | 2007-09-26 | ストライカー・コーポレーション | 形態形成蛋白質溶解型複合体，及びその組成 |
| AU681594B2 (en) * | 1992-07-31 | 1997-09-04 | Stryker Corporation | Morphogen-induced nerve regeneration and repair |
| WO1994003075A2 (en) | 1992-07-31 | 1994-02-17 | Creative Biomolecules, Inc. | Morphogen-enriched dietary composition |
| EP0661987B1 (en) | 1992-09-16 | 1998-01-14 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| JPH08503198A (ja) | 1992-11-03 | 1996-04-09 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | Ｏｐ−３誘導形態形成 |
| AU682176B2 (en) | 1993-03-04 | 1997-09-25 | Stryker Corporation | Method and compositions for recombinant osteogenic protein production |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
| ATE225666T1 (de) * | 1993-11-15 | 2002-10-15 | Celtrix Pharma | Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung |
| US5525621A (en) * | 1994-05-20 | 1996-06-11 | Cytos Pharmaceuticals Llc | Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| US6214796B1 (en) * | 1996-03-22 | 2001-04-10 | The General Hospital Corporation | Administration of polypeptide growth factors following central nervous system ischemia or trauma |
| US5820589A (en) * | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US5879908A (en) * | 1997-04-30 | 1999-03-09 | Smithkline Beecham Corporation | CRFG-1a, a target and marker for chronic renal failure |
| US7147839B2 (en) | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
-
1998
- 1998-05-05 DK DK98919715T patent/DK0980252T3/da active
- 1998-05-05 PT PT98919715T patent/PT980252E/pt unknown
- 1998-05-05 DE DE69826854T patent/DE69826854T2/de not_active Expired - Lifetime
- 1998-05-05 AT AT98919715T patent/ATE278414T1/de active
- 1998-05-05 EP EP98919715A patent/EP0980252B1/en not_active Expired - Lifetime
- 1998-05-05 AU AU72443/98A patent/AU743510B2/en not_active Ceased
- 1998-05-05 ES ES98919715T patent/ES2226125T3/es not_active Expired - Lifetime
- 1998-05-05 WO PCT/US1998/003197 patent/WO1998050060A1/en not_active Ceased
- 1998-05-05 JP JP54804898A patent/JP5033276B2/ja not_active Expired - Fee Related
- 1998-05-05 CA CA002289123A patent/CA2289123A1/en not_active Abandoned
-
2009
- 2009-08-11 US US12/583,013 patent/US20100105621A1/en not_active Abandoned
- 2009-09-11 JP JP2009211128A patent/JP2009286802A/ja not_active Withdrawn
-
2011
- 2011-04-04 US US13/079,161 patent/US8748378B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DK0980252T3 (da) | 2005-01-31 |
| EP0980252A1 (en) | 2000-02-23 |
| JP2009286802A (ja) | 2009-12-10 |
| EP0980252B1 (en) | 2004-10-06 |
| WO1998050060A1 (en) | 1998-11-12 |
| US20100105621A1 (en) | 2010-04-29 |
| AU7244398A (en) | 1998-11-27 |
| JP5033276B2 (ja) | 2012-09-26 |
| US20110257093A1 (en) | 2011-10-20 |
| ES2226125T3 (es) | 2005-03-16 |
| ATE278414T1 (de) | 2004-10-15 |
| JP2001523264A (ja) | 2001-11-20 |
| CA2289123A1 (en) | 1998-11-12 |
| DE69826854D1 (de) | 2004-11-11 |
| US8748378B2 (en) | 2014-06-10 |
| DE69826854T2 (de) | 2006-02-02 |
| AU743510B2 (en) | 2002-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT910400E (pt) | Terapias para insuficiencia renal cronica | |
| PT980252E (pt) | Terapias para insuficiencia renal aguda | |
| Mulder et al. | Treatment of nonhealing diabetic foot ulcers with a platelet‐derived growth factor gene‐activated matrix (GAM501): Results of a Phase 1/2 trial | |
| Chbinou et al. | Insulin-dependent diabetes impairs the inflammatory response and delays angiogenesis following Achilles tendon injury | |
| Gilbertie et al. | Pooled platelet-rich plasma lysate therapy increases synoviocyte proliferation and hyaluronic acid production while protecting chondrocytes from synoviocyte-derived inflammatory mediators | |
| ES2147752T3 (es) | Descontaminacion de plaquetas con 8-metoxipsoraleno. | |
| TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
| DK1238658T3 (da) | Understöttet afgivelse af et aktivt middel under anvendelse af et implanterbart system | |
| BR9707325A (pt) | Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma | |
| DK0564502T3 (da) | Vævsforseglingsmiddel og vækstfaktorholdige præparater, der fremmer accelereret sårheling | |
| FI971116L (fi) | Fotodynaaminen terapia selektiivisessä solujen inaktivoinnissa veressä sekä immuunijärjestelmän häiriötautien hoito | |
| NO20001754D0 (no) | Prostaglandinagonister og anvendelse derav for behandling av benforstyrrelser | |
| ES2069750T3 (es) | Metodos y composiciones para curar huesos. | |
| ATE273031T1 (de) | Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen | |
| ATE433461T1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
| ES2180514T3 (es) | Uso de un factor con actividad inhibidora del melanoma (mia) para reparacion de cartilagos y huesos. | |
| ATE361756T1 (de) | Insulinartiger-wachstumsfaktorbindungsprotein-4 protease | |
| ATE238796T1 (de) | Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten | |
| EP0990441A4 (en) | MEDICINES FOR TREATING DIABETIC NEPHROSIS | |
| FI952170L (fi) | Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi | |
| DE69821227D1 (de) | Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen | |
| PT1214091E (pt) | Terapias para a insuficiencia renal cronica utilizando um ou mais antaginistas de integrina | |
| FR2764389B1 (fr) | Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee | |
| ATE232738T1 (de) | Kolostrum enthaltende pharmazeutische zusammensetzungen und deren verwendung | |
| PT834316E (pt) | Utilizacao da sulbutiamina para a obtencao de composicoes farmaceuticas uteis no tratamento de certas perturbacoes psicomotoras e psico-intelectuais |